Evaluation of Study Experiences of Neuroendocrine Tumor Patients

Taking part in clinical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. This research will admit a wide range of data on the clinical study experience of neuroendocrine tumor patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future patients with neuroendocrine tumor.

NCT Number	NCT05967481
Lead Sponsor	Power Life Sciences Inc.
Conditions	Neuroendocrine Tumors
Enrollment	500 participants
Start Date	2024-08
Primary Completion	2025-08 (estimated)
Study Completion	2026-08 (estimated)
Updated on ClinicalTrials.gov	2023-08-01